New Zealand to fund GSK's Tykerb and Votrient
This article was originally published in Scrip
Executive Summary
Pharmac, New Zealand's pharmaceutical management agency, estimates that it will spend $15 million over the next five years on GlaxoSmithKline's Tykerb/Tyverb (lapatinib) for treating HER2 positive metastatic breast cancer and Votrient (pazopanib) for advanced renal cell carcinoma cancer. The agency approved the drugs, which will benefit 180 patients each year, for funding this week.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.